AMEX: VNRX
VolitionRX Ltd
Healthcare · Medical - Devices
After hours: $0.39(+1.4%) · as of 7:40 PM ET
Market Cap
$3.21M
52w High
$14.80
52w Low
$0.37
P/E
-0.10
Volume
566.42K
Outstanding Shares
8.34M
Valuation Data Insufficient
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 97.19% over the last year. Revenue grew 86.32% over the trailing twelve months. Operating margin moved from -1,779.01% to -786.69%. Free cash flow grew 10.86% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -786.69%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
5
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q4 FY26 · EPS est -$0.38 · Revenue est $554K
View